In patients with AD, increased allergen penetration through the skin due to barrier disruption, combined with filaggrin gene mutations, impaired immunoregulatory mechanisms, and the use of topical therapies, may contribute to a higher incidence of contact dermatitis compared to the general population. This evidence concerns the gene FLG and Alzheimer disease.